CINJ 070501(NJ 1205): A Phase II Study of Imatinib Mesylate and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer.

Trial Profile

CINJ 070501(NJ 1205): A Phase II Study of Imatinib Mesylate and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2014

At a glance

  • Drugs Imatinib (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Nov 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
    • 17 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Additional lead trial investigators identified as reported by New Jersey Cancer Trial Connect record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top